A Retrospective Analysis of Primary Gastrointestinal Non-Hodgkin Lymphomas: Clinical Features, Prognostic Factors and Treatment Outcomes.
MYC rearrangement
primary gastrointestinal lymphomas
prognosis
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2020
2020
Historique:
received:
04
02
2020
accepted:
21
05
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
2
7
2020
Statut:
epublish
Résumé
Primary gastrointestinal non-Hodgkin lymphoma (PGIL) is a rare hematopoietic malignancy with limited data to guide management. We analyzed the clinical characteristics and survival of 219 newly diagnosed PGIL patients. Our single-center data showed that the incidence rate of primary gastric lymphoma (PGL) was higher than that of primary intestine lymphoma (PIL). Most PGIL was B-cell originated and DLBCL was the most common pathological type both in PGL and PIL group. Univariate and multivariate analysis showed that IPI score and pathology were independent prognostic factors. The overall survival (OS) and progression-free survival (PFS) of patients with MYC rearrangement were much shorter compared to patients without MYC rearrangement indicating that MYC translocation was related to decreased survival. Neither OS nor PFS differed between patients who received chemotherapy with or without surgery. However, patients who received surgery alone had a poor prognosis. Chemotherapy is the front-line treatment for PGIL while surgery was conducted to relieve tumor-related complications or make diagnosis. MYC rearrangement predicted poor prognosis of PGIL patients.
Identifiants
pubmed: 32606752
doi: 10.2147/OTT.S248381
pii: 248381
pmc: PMC7293986
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5345-5352Informations de copyright
© 2020 Tian et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
CA Cancer J Clin. 2016 Mar-Apr;66(2):153-71
pubmed: 26773441
Nat Rev Clin Oncol. 2018 Jan;15(1):31-46
pubmed: 28857075
World J Surg Oncol. 2016 Mar 18;14:85
pubmed: 26988370
Euroasian J Hepatogastroenterol. 2018 Jan-Jun;8(1):6-10
pubmed: 29963454
Pak J Med Sci. 2017 Nov-Dec;33(6):1406-1411
pubmed: 29492068
Pathol Int. 2016 Aug;66(8):444-52
pubmed: 27439595
Cancer Control. 2018 Jan-Mar;25(1):1073274818778256
pubmed: 29779412
Acta Haematol. 2016;135(1):21-8
pubmed: 26303279
J Gastrointest Surg. 2016 Jun;20(6):1141-9
pubmed: 26992397
South Asian J Cancer. 2019 Jan-Mar;8(1):57-59
pubmed: 30766857
Blood. 2017 Sep 21;130(12):1409-1417
pubmed: 28720586
J Gastroenterol Hepatol. 2015 Oct;30(10):1485-91
pubmed: 25967274
J Gastrointest Surg. 2016 Apr;20(4):827-39
pubmed: 26676930
Gastroenterology. 2016 Jul;151(1):51-69.e14
pubmed: 27102658
Medicine (Baltimore). 2015 Nov;94(47):e2119
pubmed: 26632732